

# Molecular Cloning of Two cDNAs Encoding the Mouse Bilirubin/Phenol Family of UDP-Glucuronosyltransferases (*mUGT<sub>Br/p</sub>*)<sup>1</sup>

Ah-Ng Tony Kong,<sup>2,4</sup> Meihui Ma,<sup>2</sup> Deling Tao,<sup>2,3</sup> and Linding Yang<sup>2</sup>

Received August 17, 1992; accepted October 6, 1992

**KEY WORDS:** UDP-glucuronosyltransferases; glucuronidation; drug metabolism; bilirubin conjugation; phenol conjugation; Phase II metabolism.

## INTRODUCTION

Glucuronidation, catalyzed by UDP-glucuronosyltransferase (UGT),<sup>5</sup> is an important process in the metabolism of many drugs, carcinogens, xenobiotics, and endogenous substances such as bilirubin, steroids, and biogenic amines (1–3). UGT also plays an important role in the biosynthesis of proteoglycans, which confer important recognition properties on cell surfaces that influence cell adhesion and migration as well as the binding of growth factors and enzyme inhibitors (4). In humans, deficiency in glucuronidation has significant clinical and toxicological consequences. For example, inability to glucuronidate bilirubin may lead to its accumulation in plasma and tissues and result in jaundice. In more severe cases, patients may be at risk for bilirubin encephalopathy (kernicterus). These clinical sequelae have been observed in patients with Crigler–Najjar syndrome where there is an absence or partial deficiency in bilirubin UGT activity (5).

UGTs belong to a multigene family which comprises at least 21 distinct cDNAs in five mammalian species (5–19). Recent advances in biochemical and molecular biological approaches have given insight into the substrate specificity, function, and structure of UGT. Thus far, the human and rat bilirubin and phenol UGTs have been characterized. It was

found that there are structural similarities between the bilirubin UGTs and the phenol UGTs between and within two species. Specifically, the 3' ends of both the bilirubin and the phenol UGT are identical. To date, the structure of the mouse UGT gene is not known and so the question remains whether it will be similar to that in man. Since the mouse is one of the most widely utilized animal models for pharmacologic as well as toxicological testings of pharmaceutical compounds, it is relevant to study the mouse genes. It has been reported that there are species differences between the mouse and the rat in the regulation of UGT activity for bilirubin and phenolic substrates (20). Here, we report the cloning of two mouse liver cDNAs which encode bilirubin and phenol UGT. The first cDNA, designated *mUGT<sub>Br1</sub>*, consists of 2216 base pairs (bp) and contains 1608-nucleotide open reading frame beginning at nucleotide 16, which encodes a 535-amino acid polypeptide of 60 kDa. The second cDNA, designated *mUGT<sub>p4</sub>*, consists of 2158 bp and encodes a protein of at least 521 amino acid residues. The two cDNAs encode an identical C terminus but a variable N terminus. From the deduced amino acid sequence alignment, *mUGT<sub>Br1</sub>* shares 78, 65, 63, 61, 65, and 70% sequence homology with human *hBRI* (17), *hBr2* (17), *hPh1* (15), *hPh4* (18), and rat *rPh* (8) *rBr* (11), whereas *mUGT<sub>p4</sub>* shares 62, 61, 63, 74, 65, and 65%, respectively.

## MATERIALS AND METHODS

### Screening of a $\lambda$ gt11 cDNA Library

A mouse adult liver cDNA library in phage lambda gt11 ( $\lambda$ gt11) and the host cells (*Escherichia coli* strain Y1090) were purchased from Clontech Lab. (Palo Alto, CA). Four hundred thousand plaques at a density of ~20,000 per 150-mm plate were screened using a 426-bp *KpnI/XbaI* fragment of the human 2351-bp full-length *HUG-Br1* cDNA (16) according to the methods established in our laboratory (21) and by Ausubel *et al.* (22). The probes were prepared by random hexamer primed synthesis (Prime-a-Gene Labeling System; Promega, Madison, WI) using [ $\alpha$ -<sup>32</sup>P]dCTP (3000 Ci/mmol, NEN Dupont; 1 Ci = 37 GBq) to generate a specific activity of 1–3  $\times$  10<sup>9</sup> cpm/ $\mu$ g DNA (23). Positive plaques were replated and rescreened twice until two isolated positive plaques were used to purify phage DNA as described in (22), with minor modifications. Subfragments representing inserted cDNA in  $\lambda$ gt11 were generated by digestion with *EcoRI* and ligated into *EcoRI*-digested, phosphatase-treated plasmid Bluescript SK+ (Stratagene, La Jolla, CA). The sequences of the inserts were determined on double-stranded DNA by the dideoxynucleotide chain termination method of Sanger *et al.* (24), modified as in Sequenase Version 2.0 protocols (U.S. Biochemical Corp., Cleveland, OH). It was found that the two clones were identical and contained 1202 bp without an open reading frame and therefore are partial cDNAs (25).

### Rescreening of a $\lambda$ ZAP cDNA Library

The partial cDNA obtained above was used to rescreen a mouse liver  $\lambda$ ZAP cDNA library (Stratagene). The strategy

<sup>1</sup> The sequence data in this paper have been submitted to the EMBL/Genbank Data Library under accession number L02333. This paper was presented in part at the 21st Annual Meeting of American College of Clinical Pharmacology (ACCP), Washington, DC, September 17–19, 1992.

<sup>2</sup> Division of Clinical Pharmacology, Department of Medicine, Thomas Jefferson University, 1100 Walnut St—Rm 601, Philadelphia, Pennsylvania 19107-5563.

<sup>3</sup> Department of Biology, Eastern Michigan University, Ypsilanti, Michigan 48197.

<sup>4</sup> To whom correspondence should be addressed.

<sup>5</sup> UGT(s) is used to denote UDP-glucuronosyltransferase protein(s) and italic *UGT* with a subscript, e.g., *UGT<sub>Br1</sub>*, indicates the gene that encodes the protein.

GAATTCGGAGATCTC

SerPhePheLeuCysLeuLeuLeuAlaSerGlyLeuAlaGlnAla  
TCCTTTTTCCTGTCTGCTTCCGGCTTCGGCTTCGGCCAGGCA

1 ATGACTGTGGTGTGCTGGAGCTCGCGTTTGCTTCTGCTTCTCCGTACCTTCTGTTGTTGTGTGTTTCGGTCCCTCCACGCTGGG  
1 MetThrValValCysTrpSerSerArgLeuLeuLeuLeuLeuProTyrLeuLeuLeuCysValPheGlyProTyrAlaSerHisAlaGly

GlyArgLeuLeuValValProMetAspGlySerHisTrpPheThrMetGlnMetValValGluLysLeuIleHisArgGlyHisGluVal  
GGCAGGCTGCTGGTGGTCCCATGGATGGAAGCCACTGGTTACACATGCAGATGGTGTGGAGAACTCATTACAGAGGGCATGAGGTT  
91 AGCGTGTAGTGTCCCTATGGATGGAAGCCACTGGCTGAGTATGCTTGGAGTTATTTCAGCAGCTCCAGCAGAAAGGCGACGAAAGTTGTG  
31 ArgLeuLeuValPheProMetAspGlySerHisTrpLeuSerMetLeuGlyValIleGlnGlnLeuGlnGlnLysGlyHisGluValVal

ValValValIleProGluValSerTrpGlnLeuGlyLysSerLeuAsnCysThrValLysThrTyrSerIleSerHisThrLeuGluAsp  
GTGGTAGTCATCCCAGAGGTGAGTGGCAGCTGGGAAATCACTGAAATGTACAGTGAAGACTTACTCAATTTCTCACACTCTGGAAAGAC  
181 GTCA TAGCACCTGAAGCCCAATACACATAAAAGAAGGATCAATTTACACTCTGAGGAAGTTCCCTGTGCCATTCCAGAAAGAAAATGTG  
61 ValIleAlaProGluAlaSerIleHisIleLysGluGlySerPheTyrThrLeuArgLysPheProValProPheGlnLysGluAsnVal

LeuAspArgGluPheLysTyrLeuSerTyrThrGlnTrpLysThrProGluHisSerIleArgSerPheLeuThrGlySerAlaArgGly  
CTGGACAGAGAGTTCAAGTATTATCTTACACTCAATGGAAAACCCAGAACACAGTATACGTTCTTTCTTTGACTGGTTCAGCCAGAGGT  
271 GATTCCAGTATTGGTGGAACTTGGACGGACTGGCTTAAATCAAGATTCTTTTCTGCTCGCGCTGGTCAAAAATATATATGAAATGATGATG  
91 ThrAlaThrLeuValGluLeuGlyArgThrAlaPheAsnGlnAspSerPheLeuLeuArgValValLysIleTyrMetLysValLysArg

PhePheGluLeuThrPheSerHisCysArgSerLeuPheAsnAspLysLysLeuValGluTyrLeuLysGlnArgPhePheAspAlaVal  
TTCTTTTGAACATACTTTTCACACTGCAGGAGTTTGTTTAAACGACAAGAAGTTAGTGGAGTACTTGAAGCAGAGATTTTTTGATGCAGTG  
361 GATCCAGTATTGGTGGAACTTGGACGGACTGGCTTAAATCAAGATTCTTTTCTGCTCGCGCTGGTCAAAAATATATATGAAATGATGATG  
121 AspSerSerMetLeuLeuAlaGlyCysSerHisLeuLeuHisAsnAlaGluPheMetAlaSerLeuGluGluSerHisPheAspAlaLeu

PheLeuAspProPheAspValCysGlyLeuIleValAlaLysTyrPheSerLeuProSerValIlePheAlaArgGlyValPheCysAsp  
TTCTTTGGAACATACTTTTCACACTGCAGGAGTTTGTTTAAACGACAAGAAGTTAGTGGAGTACTTGAAGCAGAGATTTTTTGATGCAGTG  
451 GATCCAGTATTGGTGGAACTTGGACGGACTGGCTTAAATCAAGATTCTTTTCTGCTCGCGCTGGTCAAAAATATATATGAAATGATGATG  
151 LeuThrAspProPheLeuProCysGlySerIleValAlaGlnTyrLeuThrValProThrValTyrPheLeuAsnLysLeuProCysSer

TyrLeuGluGluGlyAlaGlnCysProSerLeuProSerTyrValProArgLeuPheSerLysTyrThrAspThrMetThrPheLysGlu  
TATCTTTGAAGAGGTTGCCAGTGCCCAAGTCTTCCCTTCCATATGTTCTTAGACTTTTCTCAAAAATACACAGACACCATGACTTTCAAGGAG  
541 CTGGATTAGCAGAGTACCCAAATGCCCGTCCCATTTGCTTACGTTGCCAAGAGTTTGTCTTTCAACTCAGACCGCATGAACTTCTTACAG  
181 LeuAspSerGluAlaThrGlnCysProValProLeuSerTyrValLeuLeuAlaValSerPheAsnSerAspArgMetAsnPheLeuGln

ArgValTrpAsnHisLeuIleTyrIleGluGluHisAlaPheCysSerTyrPheLeuArgThrAlaValGluValAlaSerGluIleLeu  
TATCTTTGAAGAGGTTGCCAGTGCCCAAGTCTTCCCTTCCATATGTTCTTAGACTTTTCTCAAAAATACACAGACACCATGACTTTCAAGGAG  
631 CGAGTGAAGAACGTCCTCGCGCTGTCAGAGAACTTTATGTGCAGAGTGGTTTATCCCCCTATGGTCACTTGCCACTGAAAATCTTAA  
211 ArgValLysAsnValLeuLeuAlaValSerGluAsnPheMetCysArgValValTyrSerProTyrGlySerLeuIleLeu

GlnThrProValThrMetThrAspLeuPheSerProValSerIleTrpLeuLeuArgThrAspPheValLeuGluPheProArgProVal  
CAGACCCAGTGCATGACAGACCTCTTAGCCAGTGTCTATTGTTGTTAGCAGTACTGACTTTGTGTTGGAGTTCCCCAGGCTGTG  
721 CAGAAGAGAGTACTGTCAGGATCTTCTGAGCCCTGCATCTATCTGGCTGATGAGAAGTACTTTGTGAAGATTAACCCAGGCCCATC  
241 GlnLysGlnValThrValGlnAspLeuLeuSerProAlaSerIleTrpLeuMetArgSerAspPheValLysAspTyrProArgProIle

MetProAsnMetValPheIleGlyGlyIleAsnCysLeuGlnLysLysSerLeuSerLys  
ATGCCATACTGGTCTTTATCGGTGGGATCACTGCCTCCAGAAGAAGTCACTTTCCAAAG  
811 ATGCCCAACATGGTTTTATTTGTTGGTATAAAATGGCTTCAAGAAAAGCCCTATCCAGGAAATTTGAAGCCTATGTCAACGCTCTGGG  
271 MetProAsnMetValPheIleGlyGlyIleAsnCysLeuGlnLysLysProLeuSerGlnGluPheGluAlaTyrValAsnAlaSerGly

GAGCATGTCATCGTTTCTTCTTTGGGATCCATGGTCTCAGAGATTCCGGAGAAGAAAGCCATGGAAAATTGCTGAGGCTTTGGGCAGA  
901 GluHisGlyIleValValPheSerLeuGlySerMetValSerGluIleProGluLysLysAlaMetGluIleAlaGluAlaLeuGlyArg

ATTCTCAGACGGTCTGTTGGGCTACACCGAAGTAGACCATCGAATCTTGCAAAGAACACAATTTCTGTCAAATGGTACCCCAAAAT  
991 IleProGlnThrValLeuTrpArgTyrThrGlyThrArgProSerAsnLeuAlaLysAsnThrIleLeuValLysTrpLeuProGlnAsn

GATCTGATGTCATCCAAAGACTCGGGCATTCATCACACTCTGGCTCCCATGGTATTTATGAAGGAATATGCAATGGAGTTCGCGATG  
1081 AspLeuLeuGlyHisProLysThrArgAlaPheIleThrHisSerGlySerHisGlyIleTyrGluGlyIleCysAsnGlyValProMet

GTGATGATGCCCTATTGGCGATCAGATGGCAAATGCCAAGCGCATGAAACTCGGGGAGCTGGGGTACCCCTGAATGCTCTGAAATG  
1171 ValMetMetProLeuPheGlyAspGlnMetAspAsnAlaLysArgMetGluThrArgGlyAlaGlyValThrLeuAsnValLeuGluMet

ACTGTGATGATTTGGAAAATGCCCTTAAACTGTCAACAAAGAGCTACAAGGAGAATCATGCGCTCTCCAGCCTTCCACAAG  
1261 ThrAlaAspAspLeuGluAsnAlaLeuLysThrValIleAsnAsnLysSerTyrLysGluAsnIleMetArgLeuSerSerLeuHisLys

GACCGTCTATAGAGCTCTGGACCTGGCTGTGTTCTGGGTGGAATACGTGATGAGGCACAAGGGGGCACCACCTGGCCCGGCGGCC  
1351 AspArgProIleGluProLeuAspLeuAlaValPheTrpValGluTyrValMetArgHisLysGlyAlaProHisLeuArgProAlaAla

CATGACCTACCTGGTATCAGTACCACTCCTTGGATGTGATGGCTTCTCTCGGCCATTGTGTTGACAGTGGCTTCTCATTTGCTTTAAA  
1441 HisAspLeuThrTrpTyrGlnTyrHisSerLeuAspValIleGlyPheLeuLeuAlaIleValLeuThrValValPheIleValPheLys

TGTGTGCTATGGCTGCGGAAATGCTTTGGGGGAAAGGGCGAGTGAAGAAATCACACAAATCCAAAGCCCATTTGA  
511 CysCysAlaTyrGlyCysArgLysCysPheGlyGlyLysGlyArgValLysLysSerHisLysSerLysThrHis\*\*\*

1609 GAAGTGGGGGAAGTGAAGGAGAAGTATTAGTTCAATTTATCTGATCATGTGAAACATGGAACAAGTGTAAATCCATATTGTTTGTGTTA  
1699 GGGGTTCTAGAAAATAATTCACCATACATTTATACATTCAGCACAATTTAAATAATAATAAACAATTAATTTGCTGGCCACACCCATC  
1789 AGGGAATATATGTGATGTGCTTTTCCAGTATCTTCACTCTAGACAACCTTTGCCATCTGTTGGTAAITTTACAGAAAAGTCTGGCACTCTGC  
1879 TTTCAGTGACAGCCCCACAGTTTCCCTCGTCCCGCAGCTGACGGCTTTCCTCCCTGGATTCAGACTGCCGTGGCTTCTCCAGTGT  
1969 TAGTCATTCTTCAATTGTTGCTATGCATTTATGGGTGGCAAGACCTTTGGAGCTTTGGGAGAAGAGATGAGGCTGTGACACTGATGGCCCTG  
2059 TGTGAGATAATAATTTGTTGCTGTGCGCGAAATTTGATGAAAACAAAAGTATGTTCTAAGGCAAGTACATCTTCTATTTGTTGTTCCCAACC  
2149 AAGAACTTATCAATAATTTCAATAATAATTTGTAATAAAAAAAAACCGGAAT

Fig. 1. Nucleotide and deduced amino acid sequences of mouse *UGT<sub>B7I</sub>* (bottom) and *UGT<sub>P4</sub>* (top) cDNAs. The stop codon is designated \*\*\*. Putative N-terminal signal insertion sequence, membrane-anchoring peptides, and predicted asparagine-linked glycosylation sites (for *UGT<sub>B7I</sub>*) are indicated by the double line, the solid line, and the filled diamonds, respectively. Consensus polyadenylation signal is denoted by boldface italics.

<i>m-UGT<sub>com</sub></i>	291	EFEAYVNASGEHGIVVFSLGSVMVSEIPEKKAMEIAEALGRI
<i>r-UGT<sub>com</sub></i>	285	
<i>h-UGT<sub>com</sub></i>	290	I A D K
<i>m-UGT<sub>m-1</sub></i>	292	DM EF QS D V NMT E NA W AQ
	332	PQTVLWRYTGTRPSNLAKNTILVKWLPQNDLLGHPKTRAF
	326	L A
	331	N M
	333	K KFD KT AT GH RVY K
	372	ITHSGSHGIYEGICNGVPMVMPLFGDQMDNAKRMETRGA
	366	
	371	V S K
	373	V G AN V A YH I IGI E H IAH VAK
	412	GVTLVNLEMTADDLENALKTVINNKSYPENIMRLSSLHKD
	406	
	411	SE A D
	413	A A IRT SKS VL EE E PF K AIW TI H
	452	RPiEPLDLAVFWVEYVMRHKGAPHLRPAAHDLTWYQYHSL
	446	
	451	V F
	453	Q MK R F R K LG N
	492	DVIGFLLAIVLTVVFIVFKCCAYGCRKCFGGKGRVKKSHK
	486	Y S
	491	V A T Y L K A
	493	SC A TIVLSV LLFIY FFV----- EN
	532	SKTH
	526	
	531	
	527	M NE

Fig. 2. Alignment of the deduced amino acid sequences of mouse *UGT<sub>com</sub>*, rat *UGT<sub>com</sub>*, human *UGT<sub>com</sub>*, and mouse *UGT<sub>m-1</sub>*. Differences in amino acid residues from mouse *UGT<sub>com</sub>* are indicated for each gene.

was identical to that described above. A total of 10 plaques was obtained during primary screening. The plaques were replated and rescreened twice. After the third round, five plaques were selected and *in vivo* excision of pBluescript SK vector with the cDNA inserts using R408 helper phage was performed, according to the protocols provided by the manufacturer (Stratagene). The complete nucleotide sequences of both strands of two of the clones (9-1 and A-1) were determined by dideoxy sequencing as described above.

## RESULTS AND DISCUSSION

Plaque screening of the mouse liver  $\lambda$ gt11 cDNA library ( $4 \times 10^5$  independent clones) with radiolabeled human *HUG-Br1* cDNA probes identified two UGT cDNA clones. Both clones were sequenced from both ends and found to be identical. The clone contained 1202 bp without an open reading frame (ORF) and therefore is a partial cDNA. Using this partial cDNA as a probe, we rescreened another mouse liver cDNA library and obtained two cDNA clones (9-1 and A-1), designated *mUGT<sub>Br1</sub>* and *mUGT<sub>p4</sub>*, respectively. Figure 1 shows the nucleotide sequence together with its predicted amino acid sequence for both clones. The partial cDNA obtained initially lacked 331 amino acid residues of the amino terminus (as indicated by the star at nucleotide 994). Clone 9-1 was found to have 2219 bp with a 1608-nucleotide open reading frame (ORF) encoding a 535-amino acid polypeptide of 60.1 kDa. The deduced amino acid sequence of *mUGT<sub>Br1</sub>*

contains a characteristic hydrophobic signal peptide (amino acids 10 through 30) for protein transport across the endoplasmic reticulum (26). Two potential N-linked glycosylation sites exist at amino acid asparagine (Asn) 89 and 297. A putative transmembrane hydrophobic region is located at the carboxyl terminus, which is followed by a positively charged lysine (27). The translation stop codon, TGA, is located 5' of the consensus sequences for polyadenylation (AATAAA) and a short segment of poly(A)<sup>+</sup> tail is shown in Fig. 1. Clone A-1 had 2158 bp, encoding a protein of at least 521 amino acid residues. However, it lacked the first few amino acids that correspond to the signal insertion peptide region. The two clones have identical 3' end which encode an identical C terminus (Fig. 1). Alignment of *mUGT<sub>Br1</sub>* with other transferase clones shows overall identities of 78% to *hBr1* (17), 65% to *hBr2* (17), 63% to *hPh1* (15), 61% to *hPh4* (18), 65% to *rPh* (8), and 70% to *rBr* (11), at the amino acid level. If the N-terminal half of the deduced protein sequences is considered, the identities become 67, 43, 40, 38, 37, and 45%, respectively, indicating that *mUGT<sub>Br1</sub>* is orthologous to the bilirubin form of human *hBr1* (17). When *mUGT<sub>p4</sub>* is similarly aligned, the overall identities are 62, 61, 63, 74, 65, and 65%, and the identities become 38, 35, 38, 60, 37, and 37% (for the N terminus), respectively, indicating that *mUGT<sub>p4</sub>* is orthologous to the phenol form of human HlugP4 (18).

Figure 2 shows the alignment of the mouse carboxyl common domain (*mUGT<sub>com</sub>*) of the deduced amino acid se-

quence of *mUGT<sub>Brl</sub>* (which is identical to *mUGT<sub>p4</sub>*) with that of the same regions of the mouse *UGT<sub>m-1</sub>* (19), the rat (*rUGT<sub>com</sub>*) (8,11), and the human (*hUGT<sub>com</sub>*) (15,17). Comparing the two mouse genes (*mUGT<sub>com</sub>* and *UGT<sub>m-1</sub>*) shows only 54% identity (differs in 110 residues of 244; 39% identity overall), indicating that these two genes are from different families. This is consistent with the results from the rat and human, which show that there are multiple families of UGTs in each species (2,3,28).

When we examine *UGT<sub>com</sub>*, we find that there is high homology across species. Of 244 amino acid residues, the mouse *mUGT<sub>com</sub>* differs in only four residues from the rat *UGT<sub>com</sub>*, with 98.5% identity (95% identity at the DNA level). When *UGT<sub>com</sub>* between the mouse and the human is compared (Fig. 2), only 22 residues are found to be different, with 91.1% identity (86% identity at the DNA level). The high homology of this carboxyl common terminus between human and rodents is indicative of evolutionary conservation of important biological functions across species.

Conjugation with glucuronide confers greater polarity and water solubility on the parent agents, thereby facilitating biliary and/or urinary excretion and detoxification. However, regulation of the UGT drug metabolizing enzymes also has important consequences in carcinogenesis (29,30) and toxicity (31). Questions remain as to which UGT isoenzyme(s) catalyzes such reactions and whether there is a genetic predisposition to such disease states. This can now begin to be addressed via recombinant DNA methodologies. To this end, we are in the process of establishing stable cell lines expressing the mouse UGTs.

#### ACKNOWLEDGMENTS

The authors thank Drs. Ida S. Owens and Joseph K. Ritter (HGB, NICHD, NIH) for providing the *HUG-Brl* cDNA probe and Drs. Elaine M. Tan and Carolyn L. Kong for reviewing the manuscript.

#### REFERENCES

- G. J. Dutton. *Glucuronidation of Drugs and Other Compounds*, CRC Press, Boca Raton, FL, 1980, pp. 3-78.
- T. R. Tephly and B. Burchell. UDP-glucuronosyltransferases: A family of detoxifying enzymes. *Trends Pharmacol. Sci.* 11:276-279 (1990).
- B. Burchell, D. W. Nebert, D. R. Nelson, K. W. Bock, T. Iyanagi, P. L. M. Jansen, D. Lancet, G. J. Mulder, J. R. Chowdhury, G. Siest, T. R. Tephly, and P. I. Mackenzie. The UDP glucuronosyltransferase gene superfamily: Suggested nomenclature based on evolutionary divergence. *DNA Cell Biol* 10:487-494 (1991).
- T. N. Wight and R. P. Mecham. *Biology of Proteoglycans*, Academic Press, Orlando, FL, 1987.
- A. W. Wolkoff, J. Roy Chowdhury, and I. M. Arias. Hereditary jaundice and disorders of bilirubin metabolism. In C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle (eds.), *The Metabolic Basis of Inherited Disease*, McCraw-Hill, New York, 1987, pp. 1367-1408.
- P. I. Mackenzie. Rat liver UDP-glucuronosyltransferase: Sequence and expression of a cDNA encoding a phenobarbital-inducible form. *J. Biol. Chem.* 261:6119-6125 (1986).
- P. I. Mackenzie. Rat liver UDP-glucuronosyltransferase: cDNA sequence and expression of a form glucuronidating 3-hydroxyandrogens. *J. Biol. Chem.* 261:14112-14117 (1986).
- T. Iyanagi, M. Haniu, K. Sogawa, Y. Fuji-Kuriyama, S. Watanabe, J. E. Shivey, and K. F. Anan. Cloning and characterization of cDNA encoding 3-methylcholanthrene inducible rat mRNA for UDP-glucuronosyltransferase. *J. Biol. Chem.* 261:15607-15614 (1986).
- P. I. Mackenzie. Rat liver UDP-glucuronosyltransferase: Identification of cDNAs encoding two enzymes which glucuronidate testosterone, dihydrotestosterone, and  $\beta$ -estradiol. *J. Biol. Chem.* 262:9744-9749 (1987).
- D. Harding, S. M. Wilson, M. R. Jackson, B. Burchell, M. D. Green, and T. R. Tephly. Nucleotide and deduced amino acid sequence of rat liver 17 $\beta$ -hydroxysteroid UDP-glucuronosyltransferase. *Nucl. Acid Res.* 15:936 (1987).
- H. Sato, O. Koiwai, K. Tanabe, and S. Kashiwamata. Isolation and sequencing of rat liver bilirubin UDP-glucuronosyltransferase cDNA: Possible alternative splicing of a common primary transcript. *Biochem. Biophys. Res. Commun.* 169:260-264 (1990).
- P. I. Mackenzie. The cDNA sequence and expression of a variant 17 $\beta$ -hydroxysteroid UDP-glucuronosyltransferase. *J. Biol. Chem.* 265:8699-8703 (1990).
- D. Lazard, K. Zupko, Y. Poria, P. Nef, J. Lazarovits, S. Horn, M. Khen, and D. Lancet. Odorant signal termination by olfactory UDP-glucuronosyltransferase. *Nature* 349:790-793 (1991).
- M. R. Jackson, L. R. McCarthy, D. Harding, S. Wilson, M. W. H. Coughtrie, and B. Burchell. Cloning of human liver microsomal UDP-glucuronosyltransferase cDNA. *Biochem. J.* 242:581-588 (1987).
- D. Harding, S. Fournel-Gigleux, M. R. Jackson, and B. Burchell. Cloning and substrate specificity of a human phenol UDP-glucuronosyltransferase expressed in COS-7 cells. *Proc. Natl. Acad. Sci.* 85:8381-8385 (1988).
- J. K. Ritter, Y. Y. Sheen, and I. S. Owens. Cloning and expression of human liver UDP-glucuronosyltransferase in COS-1 cells. *J. Biol. Chem.* 265:7900-7906 (1990).
- J. K. Ritter, J. M. Crawford, and I. S. Owens. Cloning of two human liver bilirubin UDP-glucuronosyltransferase cDNAs with expression in COS-1 cells. *J. Biol. Chem.* 266:1043-1047 (1991).
- R. Wooster, L. Sutherland, T. Ebner, D. Clarke, O. Da Cruze e Silva, and B. Burchell. Cloning and stable expression of a new member of the human phenol/bilirubin UDP-glucuronosyltransferase cDNA family. *Biochem. J.* 278:465-469 (1991).
- T. Kimura and I. S. Owens. Mouse UDP-glucuronosyltransferase: cDNA and complete amino acid sequence and regulation. *Eur. J. Biochem.* 168:515-521 (1987).
- N. Malik and I. S. Owens. Genetic regulation of bilirubin-UDP-glucuronosyltransferase induction by polycyclic aromatic compounds and phenobarbital in mice. *J. Biol. Chem.* 256:9599-9604 (1981).
- A.-N. T. Kong, L. Yang, M. Ma, D. Tao, and T. D. Bjornsson. Molecular cloning of the alcohol/hydroxysteroid form (*hST<sub>a</sub>*) of sulfotransferase from human liver. *Biochem. Biophys Res. Commun.* 187:448-454 (1992).
- F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (eds.). *Current Protocols in Molecular Biology*, Greene, New York, 1989.
- A. P. Feinberg and B. Vogelstein. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. *Anal. Biochem.* 132:6-13 (1983).
- F. Sanger, S. Nicklen, and A. R. Coulson. DNA sequencing with chain-terminating inhibitors. *Proc. Natl. Acad. Sci. USA* 74:5463-5467 (1977).
- A.-N. T. Kong, M. Ma, and I. S. Owens. Molecular cloning of a mouse bilirubin/phenol UDP-glucuronosyltransferase (*UGT<sub>Brl</sub>*). *J. Clin. Pharmacol.* 32:762 (1992).
- M. E. E. Watson. Compilation of published signal sequence. *Nucl. Acid Res.* 12:5145-5164 (1984).
- T. K. Rose, W. J. Welse, B. M. Sefton, F. S. Esch, and N. C.

- Ling. Vesicular stomatitis virus glycoprotein is anchored in the viral membrane by a hydrophobic domain near the COOH terminus. *Proc. Natl. Acad. Sci.* 77:3884-3888 (1980).
28. J. K. Ritter, F. Chen, Y. Y. Sheen, H. M. Tran, S. Kimura, M. T. Yeatman, and I. S. Owens. A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini. *J. Biol. Chem.* 267:3257-3261 (1992).
29. W. Lilienblum and K. W. Bock. *N*-Glucuronide formation of carcinogenic aromatic amines in rat and human liver microsomes. *Biochem. Pharmacol.* 33:2041-2046 (1984).
30. M. D. Green and T. R. Tephly. *N*-Glucuronidation of carcinogenic aromatic amines catalyzed by rat hepatic microsomal preparations and purified rat liver uridine 5'-diphosphate-glucuronosyltransferase. *Cancer Res.* 47:2028-2031 (1987).
31. P. C. Smith, A. F. McDonagh, and L. Z. Benet. Irreversible binding of zomepirac to plasma protein in vitro and vivo. *J. Clin. Invest.* 77:934-939 (1986).